- Home
- ANTX vs KPTI Comparison
ANTX vs KPTI Comparison
Compare ANTX & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANTX | KPTI |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.9M | 194.8M |
| IPO Year | 2022 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ANTX | KPTI |
|---|---|---|
| Price | $4.70 | $7.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $2.00 | ★ $16.00 |
| AVG Volume (30 Days) | 196.7K | ★ 554.0K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.56 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $1.00 | $3.65 |
| 52 Week High | $6.91 | $10.99 |
Technical Indicators
Market Signals| Indicator | ANTX | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 50.06 | 31.80 |
| Support Level | $3.91 | $6.91 |
| Resistance Level | $5.15 | $7.59 |
| Average True Range (ATR) | 0.35 | 0.75 |
| MACD | 0.01 | -0.30 |
| Stochastic Oscillator | 47.40 | 14.04 |
Price Performance
Historical ComparisonAbout ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).